Embracing Biotech Chaos With Memo's Erik van den Berg

Business Of Biotech

We love to hear from our listeners. Send us a message.

Erik van den Berg is CEO and board member at Memo Therapeutics, and he's a student of biotech chaos. In fact, he's been embracing it with intention for the past 30 years. On this episode of the Business of Biotech, he walks us through the management of that chaos in specific detail. Navigating gluttonous Covid-fueled financial markets. Achieving clinical outcomes during the pandemic. Keeping development on the rails in a protracted financial drought. Creating differentiation in crowded and noisy renal and oncology antibody therapeutic spaces. We cover it all, with van den Berg offering detailed insight into the guiding principles of navigating constant change in biotech.
Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [e-mail]
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

Capítulos

1. Embracing Biotech Chaos With Memo's Erik van den Berg (00:00:00)

2. Embracing Chaos in Biotech Building (00:00:03)

3. Navigating Chaos in Biotech Industry (00:04:38)

4. Navigating Biotech Financing and Partnerships (00:13:00)

5. Managing Biotech Challenges During COVID (00:19:57)

6. Navigating Biotech Development for Success (00:31:01)

7. Navigating Biotech Market Innovation Chaos (00:38:19)

8. Navigating Chaos in Biotech Development (00:42:31)

9. Biotech Industry Insights and Resources (00:53:14)